Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Exclusive Story A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. First Published: 1/14/2026. 
Key Takeaways - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Companies are coming to market almost every week, and a handful often offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't automatically dismiss newly public stocks—some can merit a place in buy-and-hold portfolios. Too many retirees lie awake at night, worried their savings won't last. Traditional advice and tiny returns just aren't enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible?
That's exactly what Kelly G. discovered. She calls it "life-changing," saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it's now available to everyday investors. Click here to watch the free presentation and learn how to calculate your personal Freedom Number—an One biotechnology company in the healthcare sector that recently went public may be such a case. Last Year's IPO Success Stories Last year is a strong reminder that not all IPOs are pure high-risk gambles. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its debut. While short-term traders may have profited from a spike that approached 359% within the first 30 days of listing, longer-term holders are still enjoying solid returns. Other listings belie the idea that IPOs are only for early-stage startups. Medline (NASDAQ: MDLN), a medical products and services provider founded in 1966, made its public debut in December 2025 and already has a market cap exceeding $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its widespread bacon products—waited 89 years before going public. Since its January 2025 IPO the stock is up nearly 5% and pays a dividend that currently yields 4.44% (about $1 per share annually), making it attractive to income investors. After its IPO, with shares beginning trading on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a developer of radiopharmaceuticals, is hoping to deliver similar upside in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology focuses on radiopharmaceuticals—a branch of nuclear medicine that uses radioactive drugs for diagnostics and treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with a targeting module that can seek out specific cells (for example, cancer cells) to deliver localized doses of radiation, minimizing damage to surrounding healthy tissue compared with some conventional therapies. Industry consultant Grand View Research estimated the global nuclear medicine market at nearly $18 billion in 2024 and projects it could reach about $35 billion by 2030—a compound annual growth rate of roughly 10.16%. Grand View Research also notes that North America accounts for nearly 43% of that market, with the United States as the dominant regional player—an encouraging backdrop for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding shifts in 2025 slowed healthcare listings. Aktis, which began trading on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million—one of the larger recent biotech IPO raises—giving the company a market cap of about $3.34 billion. According to the company's prospectus, Aktis' management team includes executives with experience across drug development, approval and commercialization; members of management have participated in bringing 14 FDA-approved products to market. Technically, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs built on proprietary technology intended to attack solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent large pharma from taking notice. Eli Lilly (NYSE: LLY) anchored Aktis' IPO and purchased $100 million of AKTS shares, according to Reuters. That investment builds on a 2024 collaboration between the two companies to develop tumor-targeting radiopharmaceuticals. As part of that pact, Aktis received $60 million in cash and an equity investment from Eli Lilly, with potential milestone payments that could exceed $1 billion. The backing of Eli Lilly is notable: with a market capitalization around $1.01 trillion, Lilly is among the largest drugmakers by market value, and its net income rose nearly 109% year-over-year from 2023 to 2024. Lilly is set to report Q4 and full-year 2025 results on Feb. 5, which investors will watch closely. Between its equity stake and the $100 million purchase of AKTS shares, the maker of Zepbound has a meaningful financial interest in Aktis' future success.
| 
